Review evidence on helicobacter pylori consequences and management

Zainab Abdulhadi Alabdulrahim, Maram Nader AlJishi, Maie Abdulrhman Khayat, Lama Abdullah Almalki, Nujood Shawqi Banjar, Fatimah Nader Al-Jishi, Mustafa Abdulrazaq Alhamood, Ghaith Abdullah Almalki

Abstract:

This update will review selected areas of recent H. pylori and associated disease, diagnosis and management methods. We performed an electronic search through medical databases; PubMed/Midline, Embase for all these relevant studies that were published up to December 2017, in English language and containing only human subject. H. pylori-related illness remain an important burden for worldwide healthcare systems. Gastric cancer is one of the most serious complication and its prevention by elimination of H. pylori is presently the best option. Serum pepsinogens permit the recognition of individuals at high risk for gastric cancer advancement and should be applied in screening strategies. The function of H. pylori in the pathogenesis of extragastric malignant conditions, that is colorectal cancer, in addition to nonmalignant chronic illness like Alzheimer's illness or the metabolic syndrome remains to stimulate clinical study and controversial debate. The enhancing resistance rates to conventionally utilized antibiotics require new therapeutic strategies. Confirmation of eradication using noninvasive diagnostic tests, such as a urea breath test or stool antigen assay, is now the standard of care. The medical diagnosis of latent or symptomatic H pylori, like the diagnosis of latent or symptomatic syphilis, always need to prompt therapy. Due to lowering cure rates, new and enhanced treatments are required.

Introduction:

Worldwide, the prevalence of Helicobacter pylori infection stays high, far above 50% in Asia and South America [1].In the United States, a significant reduction has been observed in the non-Hispanic white populace [2].The claim that H. pylori will ultimately vanish in westernized civilizations as a result of improved hygiene and living requirements could not be generalized. Amongst European countries, the variation in prevalence of H. pylori infection stands out. In grown-up patients offering with clinical troubles at endoscopy departments in the UK, infection with H. pylori was reported to be as low as 6.4% [3], whereas the overall seroprevalence in patients admitted to the emergency situation ward in a German University hospital was as high as 44.4% [4] In Australia, a nationwide study reported a low prevalence of H. pylori infection yet there was considerable variation (5-30%), mainly dependent upon age [5]. In nations where the prevalence decreased amongst the native populace, immigrants from high prevalence areas account for a lot of infections [6].Basic experimental research study continues to provide interesting unique elements on microbial virulence, cell signaling, immune response, and illness states associated with H. pylori infection [7]. Clinical researches fixate the relationship of H. pylori infection with gastroduodenal and extragastric condition manifestations. Much interest is guided to the development of strategies for gastric cancer prevention and for far better elimination treatments.

This update will review selected areas of recent H. pylori and associated disease, diagnosis and management methods.

Methodology:

We performed an electronic search through medical databases; PubMed/Midline, Embase for all these relevant studies that were published up to December 2017, in English language and containing only human subject. we then searched the references found in identified articles for relevant studies concerning, helicobacter pylori consequences and management. We furthermore, scanned references lists of included studies for more relevant articles.

Discussion:

Helicobacter pylori–Associated Diseases

H pylori has a long latent duration of subclinical infection during which it creates gastric mucosal inflammation and dynamic mucosal damages. Although H pylori strains vary intheir abilityto provoke inflammation, noH pylori isolates have been identified that have not been connected with symptomatic H pylori- associated illness (eg, gastric cancer or peptic ulcer) [8]. Clinical disease is thought to stand for the result of communications between the bacterium, the host, and the setting. One of the most virulent strains possess OipA, the outer inflammatory protein, and a practical cag pathogenicity island [9], [10].Strain virulence and the visibility of polymorphisms in host genetics that control the inflammatory response identify the seriousness of the inflammatory reaction that is regulated additionally (enhanced or minimized) by environmental factors, mainly diet regimen [11].

One outcome of chronic gastritis is the development of mucosal atrophy with loss of function of the normal acid-secreting section of the stomach. The degree and severity of gastritis is related straight to the threat of developing gastric cancer [12].Before the exploration of H pylori, gastritis, particularly atrophic gastritis, was known to be connected tightly with gastric cancer. Discovery of

H pylori also was the discovery of the reason for gastritis. Although the bacterium actually might not cause the cancer, it is a" essential but not sufficient" factor in causation. The World Health Organization's International Agency for Research on Cancer has identified H pylori as a Group 1 or certain carcinogen. Eradication of H pylori globally essentially will get rid of gastric cancer and gastric MALT lymphoma. The lifetime danger for an H pylori- infected private to establish peptic ulcer disease has been approximated at one in six. The threat for creating gastric cancer in nations with a high occurrence of H pylori infection ranges from 19.6% in Changle, China to 1.5% in the United Kingdom [13].These distinctions mirror distinctions in H pylori frequency and host and environmental factors.

Gastric MALT lymphomas were identified just recently. For decades these lowgrade lymphomas were called pseudolymphoma, which mirrored their indolent course and an association with gastric ulcers [14].The association of gastric MALTomas with chronic gastritis was made at about the same time that H pylori was discovered [15]; numerous subsequent studies verified the association in between H pylori infection and gastric MALToma [16].The current understanding is that most gastric MALTomas are T-cell dependent B-cell lymphomas that respond to H pylori antigens. The majority of gastric MALTomas are low-grade lymphomas and roughly 75% undergo remission adhering to removal of H pylori, which eliminates the antigenic stimulus.

A consistent association among H pylori and useful dyspepsia has not been developed. Around 10% of topics that had documented nonulcer dyspepsia and H pylori infection reacted symptomatically to H pylori eradication therapy. H pylori eradication is recommended for these patients (as it is for all patients in whom the infection is discovered) because it might result in resolution of signs, and largely prevents the subsequent development of peptic ulcer and gastric cancer in addition to transmission of the infection to others. Population-wide research studies just

recently showed that obliteration of H pylori caused a considerable reduction in the number of individuals that consulted physicians for dyspepsia or had signs and symptoms 2 years after therapy [17].

Research studies on the effect of H pylori eradication and gastroesophageal reflux disease (GERD) have been conflicting. Overwhelming proof shows that H pylori infection does not trigger GERD nor does H pylori have a considerable result on the feedback of existing GERD to treatment; nonetheless, patients who have atrophy of the gastric corpus are" secured" from symptomatic GERD due to the fact that they are incapable to make adequate acid to develop signs and symptoms irrespective of the presence of a considerable impairment of the gastroesophageal antireflux barrier [18].Therapy of H pylori in persons who have severe corpus gastritis and asymptomatic reflux might cause enhanced acid secretion and development of symptomatic GERD (uncovering of GERD). Those that have severe corpus gastritis additionally are at boosted risk for gastric cancer; consequently, development of mild, simple to treat GERD is a tiny price to pay for a decrease in cancer threat. Lastly, H pylori eradication might enhance vitamin B12 and iron absorption, and, thus, improve anemia [19].

- **Diagnostic tests for Helicobacter Pylori Infection**

The indications for testing for H pylori are displayed in Box 1. All investigators agree that the diagnosis of an active H pylori infection need to trigger therapy. Tests to diagnose whether a patient is infected with H pylori often are separated right into those that require endoscopy or those that do not require endoscopy. The choice of test depends upon problems such as cost, accessibility, clinical situation, prevalence of infection, pretest probability of infection, and existence of aspects (eg, using PPIs and anti-biotics) that may affect examination outcomes.

Like syphilis and tuberculosis, long latent periods are the rule in H pylori infection. At least 20% of individuals that are infected with H pylori create a symptomatic end result, which is a higher portion than hidden syphilis or tuberculosis [20] Unlike syphilis and tuberculosis, concealed H pylori is transmissible. Like previous projects to eradicate syphilis or tuberculosis, the questions of whom to test and when to evaluate are public health problems. Despite its value as a worldwide pathogen and the high occurrence of H pylori and H pylori-related diseases in many countries, the focus is still on identifying and dealing with subjects who have symptomatic H pylori infections (eg, peptic ulcer illness, family history of gastric cancer, or uninvestigated dyspepsia) [21].This method results in H pylori-- involved illness staying a vital cause of morbidity and death for years to come. Easy methods, such as screening (and dealing with when favorable) at the time of application for a marital relationship permit as was done for syphilis, would certainly determine instances at an age when clinical results can be prevented along with prevent transmission of the infection within family members. Such an approach would certainly lead to complete removal of H pylori and H pylori- related diseases within 30 or 40 years. Noninvasive tests include serologic examinations, urea breath tests, and stool antigen examinations [22].IgM and IgA antibody testing have not confirmed to be valuable medically, whereas anti- H pylori IgG has a good performance history. IgG anti- H pylori antibodies normally can be anticipated to be existing by 4 weeks after infection. The three main layouts for the serologic sets are ELISA, immunochromatography, and Western blotting. Urine and salivary testing for IgG antibody likewise are offered. Urine testing has proven beneficial, whereas salivary screening has not. The majority of serologic examinations have uniqueness and sensitivities of less than 90%, which makes their usefulness limited to situations with high (eg, peptic ulcer) and reduced (eg, GERD) pretest chances. For example, take into consideration the analysis of a serologic examination with 85% sensitivity and specificity in 2 patients: a duodenal ulcer (DU) patient with a pretest probability of greater than 90% and a patient

that has GERD with a pretest probability of 20%. For 100 DU patients there would be 90 with H pylori and 10 without. The number of real positives would certainly be 77 (90 85%). The variety of incorrect downsides would be 13. Real downsides would be 9 (10 85%); there would be 1 incorrect positive. Therefore, a positive outcome definitely would be an indicator for treatment (ie, 77 of 78 would certainly be true positives). On the other hand, more than 50% of the downsides (13 of 22) would be incorrect downsides, such that retesting with a test for energetic infection would certainly be suggested prior to deciding not to treat. The opposite verdict would be the case for the patient who has GERD (reduced pretest probability) where the negative outcome would certainly be extremely dependable but the favorable outcome would require confirmation. Antibody tests could stay positive for several years after H pylori eradication and have limited worth to confirm the treatment of H pylori infection. Urea breath testing gives a noninvasive method for the diagnosis of H pylori infections.

Urea breath testing has the vital advantage of being able to confirm H pylori eradication. Adhering to consumption of 13C- or 14C-urea, the urea is hydrolyzed by the H pylori urease enzyme to identified 14CO2 or 13CO2, which can be found in breath samples [22].The nonradioactive 13C examination and the radioactive 14C test have obtained US Food and Drug Administration authorization for medical diagnosis of H pylori infection. Only the 13C-urea examination has been accepted for posteradication testing. The dose of radiation in the 14C-urea test is reduced however is collective and the test is not authorized for usage in youngsters or expecting women.

H pylori in the stomach ultimately shows up in the feces, which has caused the advancement of fecal assays, consisting of H pylori society, DNA spotted by polymerase chain reaction, or H pylori antigen screening. Only feces antigen that uses enzyme immunoassay has proven to be helpful clinically with reported level of sensitivities and specificities of more than 90% [22].Stool antigen

assay likewise is useful for recording whether removal has succeeded. To stay clear of false negative outcomes, it is normally recommended that posttreatment screening with the urea breath test, histology, or society be postponed for 4 weeks to make sure that any staying organisms could repopulate the stomach. With stool antigen testing, the hold-up should be enhanced to 6 to 12 weeks [22].

Box 1: Recommendations for testing for Helicobacter pylori infection

Definite:
Duodenal or gastric ulcer (present or history of)
Gastric low-grade MALT lymphoma
Atrophic gastritis
After endoscopic resection of early cancer
Uninvestigated dyspepsia
Evaluate success of eradication therapy
Relatives of patients who have gastric cancer
Strongly recommended:
Chronic nonsteroidal anti-inflammatory drug/aspirin therapya
Chronic antisecretory drug therapy (eg, gastroesophageal reflux disease)
Relatives of patients who have duodenal ulcer
Relatives of patients who have H pylori infection
Nonulcer dyspepsia
Patient desires to be tested
All patients who are proven to have an active H pylori infection should be treated

· Treatment: the challenge to overcome failure

The efficiency of the basic first-line triple therapy is decreasing, probably from increased antibiotic resistance [22].Numerous attempts have been made to overcome treatment failure and newer programs with brand-new mixes of antibiotics have been presented including consecutive, and concomitant quadruple treatments. Pharmacological representatives have been examined with the goal to make the bacteria more susceptible to anti-biotics. Pretreatment with n-acetylcysteine as a mucolytic representative with the objective to damage the biofilm of H. pylori and thus to overcome

H. pylori antibiotic resistance has been effectively evaluated in patients [23], however more research studies are needed prior to its feasible intro in professional technique. The enhancement of probiotics as adjunctive representative is another technique. Numerous lactobacilli or their metabolic products can inhibit or get rid of H. pylori in vitro [24].A current meta-analysis examined the effects of Saccharomyces boulardii as supplements to typical triple treatment. The adjunctive therapy with S. boulardii had little effect on the eradication rate but minimized H. pylori therapyrelated negative impacts [25].A recent testimonial of the literature, consisting of all readily available randomized, double-blind, placebo-controlled trials, concluded that a selection of 'probiotic' bacteria and yeasts, consisting of Lactobacillus spp., Saccharomyces spp., Bifidobacterium spp., and Bifidobacterium clausii, when included in typical H. pylori removal routines, did not influence obliteration rates yet lowered adverse impacts such as nausea, taste disruption, looseness of the bowels, and epigastric pain, hence boosting tolerability of H. pylori elimination therapies [26]

Present treatment suggestions have been summarized in the upgraded Maastricht guidelines. PPI basic three-way therapy is confirmed as first-line therapy in regions with a clarithromycin resistance lower than 15-20%. Although clarithromycin resistance is steadily increasing worldwide, there are differences among regions [27].In a face-to-face multicenter test from Europe, a bismuth-containing quadruple therapy in a new galenic formulation accomplished removal rates above 90% and confirmed to be superior to first-line common triple (PPI, clarithromycin, amoxicillin) by roughly 25% [28].In areas with high clarithromycin resistance, bismuth-containing quadruple treatment could be recommended as first-line therapy. One more choice is consecutive treatment [29] In a research comparing 14-day common PPI-triple, 5-day nonbismuth-based concomitant quadruple, and 10-day sequential in Latin America countries, the 14-day triple still

looked like the most effective choice [30].If first-line treatment fails, the second-line choices must include different anti-biotics. If typical triple therapy was made use of, the second effort needs to be carried out with the bismuth-containing quadruple therapy. If bismuth-based quadruple fails, second-line choice needs to be levofloxacin-based triple therapy. As quinolone resistance (i.e. levofloxacin) increases, the efficacy of this program has to be kept track of and cautiously utilized in therapy of patients with chronic pulmonary infections that could have received quinolones prior to [30] After failure of second-line therapy, third-line therapy needs to be directed by antimicrobial susceptibility testing.

Conclusion:

H. pylori-related illness remain an important burden for worldwide healthcare systems. Gastric cancer is one of the most serious complication and its prevention by elimination of H. pylori is presently the best option. Serum pepsinogens permit the recognition of individuals at high risk for gastric cancer advancement and should be applied in screening strategies. The function of H. pylori in the pathogenesis of extragastric malignant conditions, that is colorectal cancer, in addition to nonmalignant chronic illness like Alzheimer's illness or the metabolic syndrome remains to stimulate clinical study and controversial debate. The enhancing resistance rates to conventionally utilized antibiotics require new therapeutic strategies. Confirmation of eradication using noninvasive diagnostic tests, such as a urea breath test or stool antigen assay, is now the standard of care. The medical diagnosis of latent or symptomatic H pylori, like the diagnosis of latent or symptomatic syphilis, always need to prompt therapy. Due to lowering cure rates, new and enhanced treatments are required.

Reference:

1. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl 1):1–6.
2. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ ethnic disparities. Am J Epidemiol 2012; 175:54–59.
3. McNulty CA, Lasseter G, Shaw I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35:1221–1230.
4. Wex T, Venerito M, Kreutzer J, et al. Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010. Clin Vaccine Immunol 2011; 18:2109–2112.
5. Pandeya N, Whiteman DC. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. J Gastroenterol Hepatol 2011; 26:1283–1289.
6. Miendje D, Vanderpas J, Bontems P, et al. Marching cohort of Helicobacter pylori infection over two decades (1988-2007): combined effects of secular trend and population migration. Epidemiol Infect 2011; 139:572–580.
7. Smith SM, Moran AP, Duggan SP, et al. Tribbles 3: a novel regulator of TLR2- mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol 2011; 186:2462–2471.
8. Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 2002;86(6):1447–66.
9. Censini S, Lange C, Xiang Z, et al. cagA pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996;93(25):14648–53.
10. Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 2000;97(13): 7533–8.
11. Vilaichone RK, Mahachai V, Tumwasorn S, et al. Gastric mucosal cytokine levels in relation to host interleukin-1 polymorphisms and Helicobacter pylori cagA genotype. Scand J Gastroenterol 2005;40(5):530–9.
12. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet 1975;2(7924):58–60.
13. Parkin DM, Whelan SL, Ferlay J, et al, editors. Cancer incidence in five continents, vol . VIII. Lyon (France): IARC Scientific Publications No. 155; 2002.
14. Perrillo RP, Tedesco FJ. Gastric pseudolymphoma. A spectrum of presenting features and diagnostic considerations. Am J Gastroenterol 1976;65(3):226–30.
15. Vanden Heule B, Van Kerkem C, Heimann R. Benign and malignant lymphoid lesions of the stomach. A histological reappraisal in the light of the Kiel classification for non-Hodgkin's lymphomas. Histopathology 1979;3(4):309–20.
16. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338(8776):1175–6.

17.] Lane JA, Murray LJ, Noble S, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter Project: randomized controlled trial. BMJ 2006;332(7535):199–204.
18. Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 2003;98(7):1462–70.
19. Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori–is it a novel causative agent in vitamin B12 deficiency? Arch Intern Med 2000;160(9):1349–53.
20. Graham DY. Can therapy ever be denied for Helicobacter pylori infection? Gastroenterology 1997;113(6 Suppl):S113–7.
21. Nakayama Y, Graham DY. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther 2004;2(4):599–610.
22. Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 1999;354(9172):30–3.
23. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011; 27:565–570.
24. Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010; 8:817–820.
25. Vitor JM, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol 2011; 63:153–164.
26. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069–1079.
27. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011; 45:960–966.
28. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377:905–913.
29. Vaira D, Zullo A, Hassan C, et al. Sequential therapy for Helicobacter pylori eradication: the time is now! Therap Adv Gastroenterol 2009; 2:317– 322.
30. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507–514.